This document presents a case study of a 10-year-old male student presenting with redness and itching in both eyes for 15 days. On examination, the patient was found to have mild eyelid edema, conjunctival congestion and papillae in both eyes. Based on the signs and symptoms, the patient was diagnosed with vernal keratoconjunctivitis (VKC). Treatment included topical medications which improved the symptoms over subsequent follow-ups. The document concludes with a discussion of VKC including its prevalence, symptoms, signs, classification, treatment options and management.
Congenital Glaucoma is one of the most common causes of irreversible childhood blindness. This presentation covers this topic in detail that can aid physicians in effective patient care.
PS: The slides in the preview look skewed, download the presentation to view the font used in Office 2012 and upwards.
Congenital Glaucoma is one of the most common causes of irreversible childhood blindness. This presentation covers this topic in detail that can aid physicians in effective patient care.
PS: The slides in the preview look skewed, download the presentation to view the font used in Office 2012 and upwards.
Retinal vein occlusion (RVO) is an obstruction of the retinal venous system by thrombus formation and may involve the central, hemi-central or branch retinal vein.
The most common aetiological factor is compression by adjacent atherosclerotic retinal arteries.
Other possible causes are external compression or disease of the vein wall e.g. vasculitis.
Retinal vein occlusion (RVO) is an obstruction of the retinal venous system by thrombus formation and may involve the central, hemi-central or branch retinal vein.
The most common aetiological factor is compression by adjacent atherosclerotic retinal arteries.
Other possible causes are external compression or disease of the vein wall e.g. vasculitis.
Dry Eye and Ocular surface diseases in diabetes mellitusDhwanit Khetwani
RELATION OF DIABETES WITH DRY EYE AND OTHER OCULAR SURFACE DISEASES, MADE FOR THE PURPOSE PROTOCOL PRESENTATION. MADE BY DR DHWANIT KHETWANI OPHTHALMOLOGY RESIDENT
The most common form is diabetic retinopathy which occurs when diabetes damages the tiny blood vessels inside the retina. Learn more about Diabetic Eye Disease. Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
3. HISTORY & CHIEF
COMPLAINTS
C/O- (OU)
• Redness,itching-15days.
• No H/o- other specific complant.
• No H/O –using glasses.
• No H/O Ocular injury.
• No H/o-recent ophthalmic consultation.
8. CONT….
RIGHT EYE(OD) LEFT EYE (OS)
AC DEEP DEEP
IRIS WNL WNL
PUPIL R/R/R R/R/R
LENS CLEAR CLEAR
FUNDUS C:D 0.3:1, HNRR,
RETINA ON
C:D 0.3:1, HNRR,
RTINA ON
14. VERNAL
KERATOCONJUNCTIVITIS
-Vernal keratoconjunctivitis (VKC) is a
chronic,
bilateral,
at times asymmetrical,
seasonally exacerbated,
allergic inflammation of the ocular surface,
involving tarsal and ⁄ or bulbar conjunctiva.
-Its exact aetiology and pathogenesis is still unclear.
15. PREVALENCE
- More common in temperate zones of Mediterranean areas.
central and west Africa, the Middle East, Japan, the Indian
subcontinent and South America.
- After the recent decline of endemic trachoma, VKC is a leading
cause of outpatient ophthalmic morbidity.
16. AGE, GENDER, GENETICS AND
ASSOCIATED DISEASES
-Starts before 10 years. (The earliest reported age is 5 months
-Resolves after puberty, usually around 4–10 years .
• Male to female ratio - varying from 4:1 to 2:1
• One third of VKC patients have multiple atopic diseases.
• In a gender- and age-matched study, a positive correltion between
eyelash length and severity of VKC has been reported.
17. SYMPTOMS
- Pruritus,
- Hyperaemia,
- Photophobia and
- Watering,
Initially seasonal may become perennial after a few years.
• Exacerbated by exposure to wind, dust, bright light, hot
weather or physical exertion associated with sweating.
18. SIGNS
-Thick mucus hyper-secretion with sticky mucous filaments,
called ‘ropy discharge’, is a characteristic of VKC.
-Transient limbal or conjunctival yellow-white points or deposits,
known as Horner–Trantas’s dots are degenerating eosinophils
and epithelial cell debris.
-The extent of pigmentation did not correlate with the severity of
symptoms and signs of VKC.
-The pigmentation persisted when the disease was inactive
20. SIGNS : PAPILLAE
1) Papillae :
- Large (> 1 mm) papillae in VKC occur at the upper tarsus.
- Size of 7–8 mm are known as cobble- stone papillae.
- Papillae size correlate positively with the persistence or
worsening of symptoms over long-term follow-up .
- Papillae become quite swollen during the active stage but persist
even during the quiescent stage.
- Limbal papillae tend to be gelatinous and confluent.
21. SIGNS:PAPILLAE GRADING
Grade 0: no papillary reaction.
Grade 1+: few papillae, 0.2 mm widespread over the tarsal
conjunctiva or around the limbus.
Grade 2+: papillae of 0.3–1 mm over the tarsal conjunctiva or at
the limbus.
Grade 3+: papillae of 1–3 mm all over the tarsal conjunctiva for
360° around the limbus.
Grade 4+: papillae of more than 3 mm over the tarsal conjunctiva
or gelatinous appearance at the limbus covering the peripheral
cornea.
22. CLASSIFICATION AND CORNEAL CHANGES OF VKC
-Palpebral, bulbar or mixed type
-Corneal changes:
-punctate epithelial keratitis,
-epithelial macroerosions,
-Shield ulcer,
- plaque formation and
- late corneal vascularization .
-Coalescence of punctate epithelial keratitis areas leads to frank
corneal epithelial erosion, leaving Bowman’s membrane intact.
23. OTHER SIGNS IN VKC
2) Pseudogerontoxon - resembles arcus senilis,
-a waxing and waning grey-white lipid deposition in the
superficial stroma of the peripheral cornea.
3)The skin of the lid and lid margin may be thick and lax.
4)Amblyopia seen among VKC may be caused by corneal opacity,
irregular astigmatism.
5) Keratoconus.
6) Dry eye syndrome,
7) Cataract and glaucoma caused by unsupervised use of topical
corticosteroids .
26. Local treatment
1.Mast cell stabilizers:
-reduce the frequency of acute exacerbations
-In some patients adding a NSAID (ketorolac, diclofenac)
may give added benefit
27. CON..
2 .Antihistamines
-for acute exacerbations but generally not for long-term use.
3.Combined preparations of an antihistamine and a
vasoconstrictor usually offer only limited relief whereas dual
action antihistamine/mast cell stabilizers are often effective.
28. Immune modulators
a. Ciclosporin 0.05% b.d.
-indicated if steroids are ineffective, inadequate or poorly
tolerated, or as a steroid-sparing agent in patients with severe
disease.
- The drug may cause ocular irritation and blurred vision
b.Tacrolimus 0.03% ointment
- effective in VKC for severe eyelid disease.
- Instillation into the fornices has been effective in modulating
conjunctival inflammation in refractory cases
29. Other measures
a.Antibiotics are used in conjunction with steroids in severe
keratopathy to prevent or treat bacterial infection.
B.Acetylcysteine :
-a mucolytic agent that is useful in VKC for dissolving
mucus filaments and deposits, and addressing early plaque
formation
30. Systemic treatment
1.Antihistamines
used to reduce itching,
promote sleep and
reduce nocturnal eye rubbing
2 .Antibiotics (doxycycline 50–100 mg daily for 6 weeks or
azithromycin 500 mg once daily for 3 days) to reduce
blepharitis-aggravated inflammation, usually in AKC
31. CON..
• Immunosuppressive agents (e.g. steroids, ciclosporin,
tacrolimus, azathioprine)
- effective at relatively low doses,unresponsive to other
measures.
-Short courses of high-dose steroids may be necessary to achieve
rapid control in severe disease.
- Monoclonal antibodies against T cells have shown some
promise in refractory cases.
4.Aspirin: useful in VKC, although the risk of Reye's syndrome
means it should be avoided in children and adolescents (the group
predominantly affected by VKC).
32. Surgery
1. Bandage contact lens wear may be appropriate to aid the
healing of persistent epithelial defects.
2. Superficial keratectomy:
- required to remove plaques or debride shield ulcers and
allow epithelialization.
- Medical treatment must be maintained until the cornea
has re-epithelialized in order to prevent recurrences.
- Excimer laser phototherapeutic keratectomy is an
alternative.
33. CON…
• Surface maintenance-restoration surgery:
- such as amniotic membrane overlay grafting or
- lamellar keratoplasty, or
• eyelid procedures such as
- botulinum toxin-induced ptosis or lateral tarsorrhaphy, may be
required for severe persistent epithelial defects or ulceration.
- Gluing may be appropriate for focal (‘punched-out’) corneal
perforations.